IL213969A0 - Combination therapies for neoplastic disorders - Google Patents

Combination therapies for neoplastic disorders

Info

Publication number
IL213969A0
IL213969A0 IL213969A IL21396911A IL213969A0 IL 213969 A0 IL213969 A0 IL 213969A0 IL 213969 A IL213969 A IL 213969A IL 21396911 A IL21396911 A IL 21396911A IL 213969 A0 IL213969 A0 IL 213969A0
Authority
IL
Israel
Prior art keywords
combination therapies
neoplastic disorders
neoplastic
disorders
therapies
Prior art date
Application number
IL213969A
Other languages
English (en)
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of IL213969A0 publication Critical patent/IL213969A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL213969A 2009-01-08 2011-07-07 Combination therapies for neoplastic disorders IL213969A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14328209P 2009-01-08 2009-01-08
PCT/US2009/046948 WO2010080170A1 (en) 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders

Publications (1)

Publication Number Publication Date
IL213969A0 true IL213969A0 (en) 2011-08-31

Family

ID=40973134

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213969A IL213969A0 (en) 2009-01-08 2011-07-07 Combination therapies for neoplastic disorders

Country Status (13)

Country Link
EP (1) EP2381942A1 (pt)
JP (1) JP2012514638A (pt)
KR (1) KR20110116153A (pt)
CN (1) CN102341107A (pt)
AU (1) AU2009336141A1 (pt)
BR (1) BRPI0924041A2 (pt)
CA (1) CA2749261A1 (pt)
IL (1) IL213969A0 (pt)
MX (1) MX2011007384A (pt)
RU (1) RU2011133093A (pt)
SG (1) SG172922A1 (pt)
WO (1) WO2010080170A1 (pt)
ZA (1) ZA201105755B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CA3116731A1 (en) * 2018-10-19 2020-04-23 Senhwa Biosciences, Inc. Combinations for immune-modulation in cancer treatment
CN114869903A (zh) * 2022-06-14 2022-08-09 苏天生命科技(苏州)有限公司 巴弗洛霉素a1在优化急性淋系白血病化疗组合药物中的应用
US12269826B1 (en) * 2023-11-16 2025-04-08 King Faisal University 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
WO2008127707A1 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling

Also Published As

Publication number Publication date
CA2749261A1 (en) 2010-07-15
CN102341107A (zh) 2012-02-01
BRPI0924041A2 (pt) 2016-01-26
EP2381942A1 (en) 2011-11-02
RU2011133093A (ru) 2013-02-20
AU2009336141A1 (en) 2011-08-11
MX2011007384A (es) 2011-12-14
ZA201105755B (en) 2012-04-25
SG172922A1 (en) 2011-08-29
KR20110116153A (ko) 2011-10-25
WO2010080170A1 (en) 2010-07-15
JP2012514638A (ja) 2012-06-28

Similar Documents

Publication Publication Date Title
SG10201404528SA (en) Gene therapy for neurodegenerative disorders
ZA201204615B (en) Combination therapy for copd
EP2485727A4 (en) PYRROLOPYRAZOLE FOR THE TREATMENT OF CNS DISEASES
ZA201203342B (en) Treatments for gastrointestinal disorders
ZA201306971B (en) Coupler support mechanism
PL2536742T3 (pl) Leczenie zaburzeń żołądkowo-jelitowych
ZA201202346B (en) Therapeutic agent for mood disorders
ZA201105755B (en) Combination therapies for neoplastic disorders
IL207906A0 (en) Treatment for ocular-related disorders
GB0916997D0 (en) Combination therapy
GB0918626D0 (en) Therspeutics for neurological disorders
GB0907973D0 (en) Combination therapy
GB201306866D0 (en) Neurodegenerative Disorders
GB0915543D0 (en) Nasal therapies for CNS conditions
GB0711403D0 (en) Therapy for immune disorders
AU2009905647A0 (en) Combination for treating metabolic disorders
GB0917199D0 (en) Metabolic disorders